The Technical Analyst
Evaxion Biotech A/S [EVAX]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Evaxion Biotech A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.46% $4.18
/ 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 21.80 mill |
| EPS: | -8.10 |
| P/E: | -0.520 |
| Earnings Date: | May 29, 2024 |
| SharesOutstanding: | 5.22 mill |
| Avg Daily Volume: | 0.0967 mill |
| RATING 2024-04-26 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.520 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.520 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.723 (-141.23%) $-5.90 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.67 - 4.39 ( +/- 8.98%) |
| ATR Model: 14 days |
Forecast:
16:00 - $4.02
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.02
Forecast 2: 16:00 - $4.02
Forecast 3: 16:00 - $4.02
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.18 (1.46% ) |
| Volume | 0.0247 mill |
| Avg. Vol. | 0.0967 mill |
| % of Avg. Vol | 25.57 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EVAX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:24 | sell | $4.19 | N/A | Active |
|---|
EVAX
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Latest Press Releases
2024-04-17 08:00:00 - Press Release
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine Evx-01
Copenhagen, denmark, april 17, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, announces that the first patient in its evx-01 phase 2 trial in metastatic melanoma received the last vaccine dose in combination with keytruda® (nct05309421).
2024-04-02 07:00:00 - Press Release
Evaxion And Undisclosed Collaborator Announce Encouraging Results For Evx-b1 Vaccine Antigens Against Staphylococcus Aureus Infection
Copenhagen, denmark, april 02, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from evaxion's preclinical evx-b1 vaccine candidate against staphylococcus aureus (s. aureus). in the animal studies, the evx-b1 antigens significantly reduced disease burden. currently, the two companies are engaged in discussions regarding the path forward.
2024-03-27 07:30:00 - Press Release
Evaxion Announces Business Update And Full Year 2023 Financial Results
Copenhagen, denmark, march 27, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.
2024-03-19 07:30:00 - Press Release
Evaxion Hosts R&d Day And Unveils The Broad Potential Of Its Ai-immunology™ Platform
Copenhagen, denmark, march 19, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) ("evaxion" or the "company"), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today hosts a research & development (r&d) day focusing on its core ai-immunology™ platform. the event will be hosted at our facilities in hØrsholm, denmark, between 14.00 – 18.00 cet / 9.00 a.m. - 1.00 p.m. est and can be accessed remotely here.
2024-02-29 07:30:00 - Press Release
Evaxion To Host R&d Day On March 19, 2024, Highlighting Its Latest Technology Innovations
Copenhagen, denmark, feb. 29, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announces that it will host a research & development (r&d) day focusing on its core ai-immunology™ platform on march 19, 2024, at 14:00 - 18:00 cet / 8:00 a.m. - 12:00 a.m. est.
Latest News
2024-04-03 12:31:08 - Zacks Investment Research
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
2024-04-02 14:10:02 - Seeking Alpha
Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 2, 2024 9:00 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Richard Ramanius - Redeye Christian Kanstrup Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results.
2024-03-27 13:52:58 - InvestorPlace
EVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023
Evaxion Biotech (NASDAQ: EVAX ) just reported results for the fourth quarter of 2023. Evaxion Biotech reported earnings per share of -$1.60.
2024-01-24 08:32:30 - InvestorPlace
Why Is Evaxion Biotech (EVAX) Stock Up 30% Today?
Evaxion Biotech (NASDAQ: EVAX ) stock is on the rise Wednesday after the company revealed a stake held by Merck (NYSE: MRK ). A filing with the Securities and Exchange Commission (SEC) notes that Merck now holds an 11.4% stake in Evaxion Biotech.
2023-09-21 15:02:09 - Zacks Investment Research
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.
2023-08-22 17:34:06 - Seeking Alpha
Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Conference Call August 22, 2023 10:00 AM ET Company Participants Per Norlen - Chief Executive Officer Jesper Nyegaard Nissen - Chief Operating Officer and Interim Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and thank you for standing by.
2023-07-31 07:00:00 - GlobeNewsWire
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
COPENHAGEN, Denmark, July 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA.
2023-03-14 16:30:00 - GlobeNewsWire
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.
2022-12-15 07:48:00 - GlobeNewsWire
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.
2022-09-23 15:32:36 - PennyStocks
Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today
High volume penny stocks to watch before next week. The post Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.